Kynteles (Vedolizumab Vials) 300mg

Vedolizumab works by selectively binding to the α4β7 integrin on the surface of white blood cells. This binding inhibits the trafficking of these cells to the gut, reducing inflammation and the associated symptoms of inflammatory bowel diseases. By targeting this specific pathway, Vedolizumab minimizes systemic immune suppression, focusing its effects on the gastrointestinal tract.

The usual dose of Kynteles is determined by a healthcare professional based on the patient’s condition and response to treatment. The typical dosing regimen involves an initial infusion followed by subsequent infusions at specified intervals. Always follow the prescription and instructions provided by your doctor.

The safety of Kynteles during pregnancy and breastfeeding has not been established. Pregnant or breastfeeding women should consult their doctor before using this medication to weigh the potential benefits and risks.

To order Kynteles from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will reply with pricing, availability, shipping, and the import paperwork.

Kynteles is a selective antagonist of the α4β7 integrin, focusing its effects on the gastrointestinal tract with minimal systemic immune suppression. Compared to other treatments like corticosteroids or broader immunosuppressants, Kynteles offers a targeted approach that may reduce the risk of systemic side effects. However, the choice of treatment depends on individual patient factors and should be discussed with a healthcare professional.

Kynteles should be stored at 2-8°C, kept refrigerated, protected from light, and not frozen or shaken. Proper storage is crucial to maintain the medication’s efficacy and safety. Always follow the storage instructions provided with the product.

Kynteles is administered as an intravenous infusion by a healthcare professional. The infusion is typically given over a period of time, and the patient is monitored during and after the infusion to ensure safety and efficacy. Self-administration is not recommended.

The most serious risks associated with Kynteles include severe infections, progressive multifocal leukoencephalopathy (PML), allergic reactions, severe liver injury, and severe skin reactions. Patients should be monitored closely for signs of these complications, and any concerns should be reported to a healthcare professional immediately.

Kynteles should not be used by individuals who are allergic to Vedolizumab or any of its components, those with active severe infections, or patients with a history of serious infections. It is also not recommended for children under 18 years of age, and its safety during pregnancy and breastfeeding has not been established. Always consult a healthcare professional before starting any new medication.